Table 7.
Sites selected by the MCFS as significant for resistance to Tenofovir (NRTI). Only the top-scoring property is presented per site. Prevalence of mutations in the data and MCFS score are reported.
| Rank | Site | Property | Score | Prevalence | Status | |
|---|---|---|---|---|---|---|
| 1 | P215 | E oct-wat. | 37.66 | 0.53 | Known for NRTIs (abacavir, didanosine, stavudine, tenofovir, zidovudine) | * |
| 3 | P184 | E oct-wat. | 26.41 | 0.49 | Known for NRTIs (abacavir, didanosine, lamivudine) | + |
| 10 | P67 | vdW vol. | 17.81 | 0.12 | Known for NRTIs (abacavir, stavudine, tenofovir, zidovudine) | * |
| 13 | P210 | isoel. point | 15.27 | 0.29 | Known for NRTIs (abacavir, stavudine, tenofovir, zidovudine) | * |
| 19 | P41 | polarity | 13.95 | 0.37 | Known for NRTIs (abacavir, didanosine, stavudine, tenofovir, zidovudine) | * |
| 27 | P75 | E oct-wat. | 12.04 | 0.09 | Known for NRTIs (stavudine) | + |
| 30 | P203 | freq. turn | 10.62 | 0.15 | Unknown | +++ |
| 31 | P65 | isoel. point | 10.46 | 0.06 | Known for NRTIs (abacavir, didanosine, lamivudine, tenofovir) | * |
| 38 | P219 | E sol. wat. | 9.28 | 0.31 | Known for NRTIs (didanosine, stavudine, zidovudine) | + |
| 47 | P43 | freq. helix | 8.09 | 0.14 | Unknown | +++ |
| 48 | P44 | E oct-wat. | 8.07 | 0.11 | Known for NRTIs (tenofovir) | * |
| 56 | P35 | polarity | 6.93 | 0.28 | Unknown | +++ |
| 57 | P69 | vdW vol. | 6.89 | 0.16 | Known for NRTIs (abacavir, didanosine, lamivudine, stavudine, tenofovir, zidovudine) | * |
| 58 | P101 | freq. helix | 6.74 | 0.12 | Known for NNRTIs (efavirenz, etravirine, nevirapine) | ++ |
| 65 | P74 | E oct-wat. | 6.26 | 0.16 | Known for NRTIs (abacavir, didanosine, tenofovir) | * |
| 74 | P70 | isoel. point | 5.85 | 0.28 | Known for NRTIs (didanosine, stavudine, tenofovir, zidovudine) | * |
| 77 | P200 | polarity | 5.38 | 0.31 | Unknown | +++ |
| 91 | P135 | polarity | 4.71 | 0.38 | Unknown | +++ |
| 94 | P208 | isoel. point | 4.64 | 0.11 | Unknown | +++ |
Symbols represent the status of a site:
*
Sites known to contribute to resistance to Tenofovir;
+
Sites where mutations are associated with resistance to some NRTI drugs but not to Tenofovir;
++
Sites where mutations contribute to resistance to NNRTI drugs;